SCHEMBL4975293

SCHEMBL4975293

CN(C)c1cccc2ncn(CC(=O)NCc3ccc(C(C)(C)C)cc3)c12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
TRPV1 Q8NER1 1/20 0.46
TP53 P04637 3/20 0.41
NPC1 O15118 3/20 0.41
RAB9A P51151 3/20 0.41
TSHR P16473 2/20 0.41
EPHX2 P34913 2/20 0.41
NR1H4 Q96RI1 2/20 0.41
GAA P10253 2/20 0.40
ENPP2 Q13822 2/20 0.40
ALDH1A1 P00352 1/20 0.40
KMT2A Q03164 2/20 0.39
GLA P06280 1/20 0.39
MAPK1 P28482 1/20 0.39
POLB P06746 1/20 0.39
THRB P10828 1/20 0.39
MEN1 O00255 1/20 0.39
MAPT P10636 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4973583 0.86 LMNA (0.52) LMNASMN1; SMN2L3MBTL1TRPV1TP53
SCHEMBL4975771 0.85 LMNA (0.54) LMNASMN1; SMN2L3MBTL1TRPV1TP53
SCHEMBL3038445 0.85 TRPV1 (0.55) LMNASMN1; SMN2L3MBTL1TRPV1TP53
SCHEMBL4457066 0.84 LMNA (0.53) LMNASMN1; SMN2L3MBTL1TRPV1TP53
SCHEMBL4976192 0.84 LMNA (0.50) LMNASMN1; SMN2L3MBTL1TRPV1TP53
SCHEMBL4974450 0.84 TRPV1 (0.51) LMNASMN1; SMN2L3MBTL1TRPV1TP53
SCHEMBL3045467 0.84 SMN1; SMN2 (0.49) LMNASMN1; SMN2L3MBTL1TRPV1TP53
SCHEMBL4976631 0.84 SMN1; SMN2 (0.49) LMNASMN1; SMN2L3MBTL1TRPV1TP53
SCHEMBL3044801 0.83 LMNA (0.48) LMNASMN1; SMN2L3MBTL1TRPV1TP53
SCHEMBL3046393 0.82 KMT2A (0.48) LMNASMN1; SMN2L3MBTL1TRPV1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080015222-A1 New Heterocyclic Amides ASTRAZENECA AB (SE) 2008-01-17 US claimed
EP-1797067-A1 NEW HETEROCYCLIC AMIDES AstraZeneca AB (SE) 2007-06-20 EP claimed
WO-2006033620-A1 NEW HETEROCYCLIC AMIDES ASTRAZENECA AB (SE) 2006-03-30 WO claimed
US-20080015222-A1 New Heterocyclic Amides ASTRAZENECA AB (SE) 2008-01-17 US disclosed
EP-1797067-A1 NEW HETEROCYCLIC AMIDES AstraZeneca AB (SE) 2007-06-20 EP disclosed
WO-2006033620-A1 NEW HETEROCYCLIC AMIDES ASTRAZENECA AB (SE) 2006-03-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080015222-A1 New Heterocyclic Amides AADAC, AVPR2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 LMNA 2368/4885SMN1; SMN2 4341/4885L3MBTL1 4863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.